Autres langues Spruce Biosciences, Inc.

Actions

SPRB

US85209E1091

Temps réel estimé Cboe BZX Autres places de cotation 21:59:26 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,588 ^USD	+1,41 %		+4,65 %	-79,86 %

09/07	Spruce Biosciences, Inc. (NasdaqGS:SPRB) a conclu l'acquisition de la quasi-totalité des droits, titres, intérêts et actifs de l'Avexitide d'Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) pour un montant de 10 millions de dollars.	CI
13/06	SPRUCE BIOSCIENCES, INC. : Oppenheimer réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA	11/07
Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	09/07
Spruce Biosciences, Inc. stalking horse asset purchase agreement to acquire Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	14/06
Spruce Biosciences Recognized as a Bay Area Best Place to Work	06/06
Spruce Biosciences und HMNC Brain Health kündigen strategische Zusammenarbeit zur Entwicklung einer Behandlung für Major Depressive Disorder (MDD) an	04/06
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)	04/06
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder	04/06
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024	03/06
Spruce Biosciences, Inc. Presents Phase 2 POWER Study Results of Tildacerfont for Treatment of Polycystic Ovary Syndrome at ENDO 2024	03/06
Spruce Biosciences : ENDO 2024	01/06
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference	23/05
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society	22/05
Spruce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates	13/05
Spruce Biosciences : Pediatric Endocrine Society 2024 Annual Meeting	03/05
Spruce Biosciences : Failure to Satisfy Listing Rule - Form 8-K	02/05
Spruce Biosciences to Participate in May Investor Conferences	01/05
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	30/04
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting	22/04
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB	05/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Spruce Biosciences, Inc.

Actions

SPRB

US85209E1091

Autres langues

Filtres